Status: Recruiting
Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma
This is an open-label, multicenter Phase 1b/2a study to evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of GNS561 in combination with trametinib in Advanced KRAS Mutated Cholangiocarcinoma after failure of standard-of-care first line therapy
Participants needed: 98
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: GenfitUpdated: Jul 13, 2026Locations: 11
Eligibility criteria
Histologically confirmed intrahepatic CCA with a documented KRAS mutation. [+9]
Previous treatment with a MEK inhibitor or autophagy inhibitor. [+14]